BCL6 Regulates Brown Adipocyte Dormancy to Maintain Thermogenic Reserve and Fitness

Total Page:16

File Type:pdf, Size:1020Kb

BCL6 Regulates Brown Adipocyte Dormancy to Maintain Thermogenic Reserve and Fitness BCL6 regulates brown adipocyte dormancy to maintain thermogenic reserve and fitness Vassily I. Kutyavina and Ajay Chawlaa,b,c,1,2 aCardiovascular Research Institute, University of California, San Francisco, CA 94143-0795; bDepartment of Physiology, University of California, San Francisco, CA 94143-0795; and cDepartment of Medicine, University of California, San Francisco, CA 94143-0795 Edited by Steven A. Kliewer, The University of Texas Southwestern Medical Center, Dallas, TX, and approved July 1, 2019 (received for review April 30, 2019) Brown adipocytes provide a metabolic defense against environ- in metabolic tissues, such as adipocytes and liver, where its mental cold but become dormant as mammals habituate to warm functions are just beginning to be investigated (18–22). For ex- environments. Although dormancy is a regulated response in brown ample, a recent report found that deletion of Bcl6 in all adipo- adipocytes to environmental warmth, its transcriptional mecha- cytes increased de novo lipogenesis, resulting in selective nisms and functional importance are unknown. Here, we identify B expansion of subcutaneous white adipose tissue (WAT) and cell leukemia/lymphoma 6 (BCL6) as a critical regulator of dormancy protection from obesity-induced insulin resistance (21). Al- in brown adipocytes but not for their commitment, differentiation, though these studies suggest a potential role for BCL6 in fatty or cold-induced activation. In a temperature-dependent manner, acid metabolism, the role of BCL6 in brown adipocyte biology BCL6 suppresses apoptosis, fatty acid storage, and coupled respi- has not been explored. ration to maintain thermogenic fitness during dormancy. Mecha- Here, we investigated the regulatory functions of BCL6 in nistically, BCL6 remodels the epigenome of brown adipocytes to both metabolically active and dormant brown adipocytes. We enforce brown and oppose white adipocyte cellular identity. Thus, found that loss of BCL6 did not impair the commitment, dif- unlike other thermogenic regulators, BCL6 is specifically required ferentiation, or adrenergic activation of brown adipocytes, but it for maintaining thermogenic fitness when mammals acclimate to environmental warmth. selectively impaired their thermogenic capacity during dor- mancy. Thus, unlike other thermogenic regulators that act PHYSIOLOGY metabolism | transcription | thermogenesis | brown fat | acclimation downstream of the sympathetic nervous system, our data suggest that BCL6 acts in parallel with the sympathetic nervous system to reinforce brown adipocyte cellular identity during dormancy. n mammals, brown and beige adipocytes generate heat (ther- Imogenesis) through fuel oxidation and uncoupled respiration Results to defend core temperature in cold environments (1–4). As BCL6 Maintains Thermogenic Capacity of BAT during Dormancy. BCL6 mammals acclimate to warm environments, their need for ther- is expressed in mature BAT and differentiating brown adipocytes mogenesis decreases, resulting in the entry of brown and beige (SI Appendix, Fig. S1 A and B), where its functions are not well adipocytes into a dormant state to conserve energy and prevent hyperthermia (1, 4). For example, depots of brown adipose tissue (BAT) in adult humans are largely dormant but can be activated Significance by prolonged exposure to environmental cold or adrenergic ag- onists (5–9). Although entry of thermogenic adipocytes into During exposure to environmental cold, brown adipocytes pro- dormancy is a well-appreciated adaptation to environmental tect against hypothermia by generating heat (thermogenesis). In warmth, the factors and mechanisms that regulate dormancy in warm environments, brown adipocytes become inactive or dor- BAT remain unknown. mant but still maintain their identity and thermogenic capacity, While both brown and beige adipocytes undergo dormancy allowing rapid reactivation of thermogenesis upon subsequent during acclimation to environmental warmth, their molecular, cold exposure. Our understanding of the dormant state and its metabolic, and epigenetic states are quite distinct. For example, regulation is very limited. Here, we show that the transcription beige adipocytes lose virtually all of their thermogenic capacity factor B cell leukemia/lymphoma 6 (BCL6) is specifically required during acclimation to environmental warmth, whereas brown ad- for maintenance of thermogenic capacity during dormancy in ipocytes retain a significant portion of their thermogenic capacity brown adipocytes. Mechanistically, BCL6 drives a gene expression even after remaining dormant for many weeks (10, 11). This dis- program that promotes survival, fatty acid oxidation, and tinction between beige and brown adipocytes is also observed at uncoupled respiration. Thus, unlike other transcription factors the level of the epigenome. For example, the enhancer landscape that regulate cold-induced thermogenesis, BCL6 is specifically of beige adipocytes undergoes profound remodeling during ad- required for maintaining thermogenic fitness during adaptation aptation to warmth, becoming almost indistinguishable from that to environmental warmth. of white adipocytes (10). In contrast, brown adipocytes largely Author contributions: V.I.K. and A.C. designed research; V.I.K. performed research; V.I.K. maintain their chromatin state during dormancy, which allows and A.C. analyzed data; and V.I.K. and A.C. wrote the paper. them to maintain their thermogenic capacity (10). However, it is The authors declare no conflict of interest. not known what factors contribute to maintenance of a stable This article is a PNAS Direct Submission. epigenetic state during brown adipocyte dormancy. This open access article is distributed under Creative Commons Attribution-NonCommercial- B cell leukemia/lymphoma 6 (BCL6), a sequence-specific NoDerivatives License 4.0 (CC BY-NC-ND). transcriptional repressor, is expressed in many cell types but Data deposition: The data reported in this paper have been deposited in the Gene Ex- has been best studied in the immune system. In germinal center pression Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession no. B cells, it plays an essential role in the germinal center reaction GSE122746). by repressing genes involved in DNA damage response, apo- 1To whom correspondence may be addressed. Email: [email protected]. ptosis, cell activation, and plasma cell differentiation (12, 13). 2Present address: Merck Research Labs, SAF-803, South San Francisco, CA 94080. BCL6 is also required for the differentiation of follicular helper This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. T cells and modulates the inflammatory activation of macro- 1073/pnas.1907308116/-/DCSupplemental. phages (14–17). Outside the immune system, BCL6 is expressed Published online August 2, 2019. www.pnas.org/cgi/doi/10.1073/pnas.1907308116 PNAS | August 20, 2019 | vol. 116 | no. 34 | 17071–17080 Downloaded by guest on September 24, 2021 understood. To investigate the role of BCL6 in brown adipocyte pothesis that BCL6 is important for maintenance of thermogenic biology, we crossed Bcl6f/f mice on C57BL6/J background with capacity in dormant BAT. Ucp1Cre, AdipoqCre,andMyf5Cre to generate conditional knockouts To investigate the role of BCL6 in BAT dormancy, we bred of BCL6 in BAT (Bcl6f/fUcp1Cre), pan-adipose (Bcl6f/fAdipoqCre), and reared mice at thermoneutrality (30 °C), a warm environ- + and Myf5 somitic brown adipocyte precursors (Bcl6f/fMyf5Cre), ment that minimizes thermogenesis and promotes entry of BAT respectively (Fig. 1A). In contrast to a previous study that impli- into its dormant state. Although thermoneutral housing did not cated BCL6 in commitment and differentiation of adipocyte alter expression of the BCL6 protein in BAT (SI Appendix, Fig. + precursors (20), we found that BCL6 was not required in Myf5 S1D), loss of BCL6 had a profound effect on the thermogenic precursors for the development of the brown adipocyte lineage competence of dormant BAT. For example, during a cold chal- (Fig. 1B). Furthermore, in mice raised at the normal vivarium lenge from 30 °C to 10 °C, core temperature rapidly declined in temperature of 22 °C, BCL6 was not required for cold-induced Bcl6f/fUcp1Cre and Bcl6f/fMyf5Cre mice, resulting in severe hypo- thermogenesis, as evidenced by normal core body temperature thermia (Fig. 1E and SI Appendix, Fig. S1E). In both conditional and survival of Bcl6f/fUcp1Cre and Bcl6f/fAdipoqCre mice upon acute knockouts, the inability to maintain core temperature was uni- exposure to 4 °C (Fig. 1 C and D and SI Appendix,Fig.S1C). Since formly lethal, whereas the majority of the control animals were BCL6 was not required for BAT thermogenesis in cold-adapted able to survive the cold challenge after adaptation to thermo- mice (i.e., raised at 22 °C), we considered the alternative hy- neutrality (Fig. 1F and SI Appendix, Fig. S1F). Bcl6f/f Bcl6f/fUcp1Cre f/f f/f Cre Bcl6f/f Bcl6f/fUcp1Cre A Bcl6f/f Bcl6f/f B C Bcl6 Bcl6 Ucp1 D Cre Cre 40 Bcl6f/f Adipoq Ucp1 100 C) 38 BCL6 36 Bcl6f/fAdipoqCre Bcl6f/fMyf5Cre 50 Survival (%) 34 Lamin B1 T : 22 C 4 C Ta: 22 C 4 C Core temperature ( a 32 0 02468 02468 Time (hours) Time (hours) Bcl6f/f Bcl6f/fUcp1Cre EFf/f f/f Cre G H Bcl6 Bcl6 Ucp1 Bcl6f/f Bcl6f/fUcp1Cre p 0.0001 40 T : 30 C 10 C 80 p 0.0001 a f/f 150 100 Bcl6 C) NE p=0.0004 Bcl6f/fUcp1Cre 35 60 NE 100 p=0.0003 p=0.0004 30 (ml/hr) 40 (ml/hr) 2 50 2 VO VO 50 25 Survival (%) 20 Core temperature ( T : 30 C 10 C a Ta=30 C Ta=22 C 20 0 0 0 02468 02468 0 20406080 02550 Time (hours) Time (hours) Time (min) Time (min) Veh CL-316,243 Cre Cre f/f f/f f/f f/f 1 f/f 1 p Bcl6 p I f/f J K L Bcl6 f/f Cre Bcl6 Bcl6 Uc Bcl6 Ucp1 Bcl6 Bcl6 Uc 200 Bcl6f/fUcp1Cre C) 40 p 0.0001 p0.0001 f/f 150 Bcl6 NE p=0.0002 35 100 p=0.0068 (ml/hr) 2 Cre by PKA 1 p VO 50 Phosphorylation Uc p=0.0189 f/f 30 Ta: 22 C 30 C (6 wks) 10 C 0 ADRB3 Bcl6 0 20406080 surface temperature ( iBAT 015 HSP90 Time (min) Time at 4 C (mins) Fig.
Recommended publications
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman Et Al
    US 20150337275A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0337275 A1 Pearlman et al. (43) Pub. Date: Nov. 26, 2015 (54) BOCONVERSION PROCESS FOR Publication Classification PRODUCING NYLON-7, NYLON-7.7 AND POLYESTERS (51) Int. C. CI2N 9/10 (2006.01) (71) Applicant: INVISTATECHNOLOGIES S.a.r.l., CI2P 7/40 (2006.01) St. Gallen (CH) CI2PI3/00 (2006.01) CI2PI3/04 (2006.01) (72) Inventors: Paul S. Pearlman, Thornton, PA (US); CI2P 13/02 (2006.01) Changlin Chen, Cleveland (GB); CI2N 9/16 (2006.01) Adriana L. Botes, Cleveland (GB); Alex CI2N 9/02 (2006.01) Van Eck Conradie, Cleveland (GB); CI2N 9/00 (2006.01) Benjamin D. Herzog, Wichita, KS (US) CI2P 7/44 (2006.01) CI2P I 7/10 (2006.01) (73) Assignee: INVISTATECHNOLOGIES S.a.r.l., (52) U.S. C. St. Gallen (CH) CPC. CI2N 9/13 (2013.01); C12P 7/44 (2013.01); CI2P 7/40 (2013.01); CI2P 13/005 (2013.01); (21) Appl. No.: 14/367,484 CI2P 17/10 (2013.01); CI2P 13/02 (2013.01); CI2N 9/16 (2013.01); CI2N 9/0008 (2013.01); (22) PCT Fled: Dec. 21, 2012 CI2N 9/93 (2013.01); CI2P I3/04 (2013.01); PCT NO.: PCT/US2012/071.472 CI2P 13/001 (2013.01); C12Y 102/0105 (86) (2013.01) S371 (c)(1), (2) Date: Jun. 20, 2014 (57) ABSTRACT Embodiments of the present invention relate to methods for Related U.S. Application Data the biosynthesis of di- or trifunctional C7 alkanes in the (60) Provisional application No.
    [Show full text]
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • The CARMA3-Bcl10-MALT1 Signalosome Drives NF-Κb Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer
    Author Manuscript Published OnlineFirst on December 19, 2017; DOI: 10.1158/0008-5472.CAN-17-1089 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Molecular and Cellular Pathobiology .. The CARMA3-Bcl10-MALT1 Signalosome Drives NF-κB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer. Prasanna Ekambaram1, Jia-Ying (Lloyd) Lee1, Nathaniel E. Hubel1, Dong Hu1, Saigopalakrishna Yerneni2, Phil G. Campbell2,3, Netanya Pollock1, Linda R. Klei1, Vincent J. Concel1, Phillip C. Delekta4, Arul M. Chinnaiyan4, Scott A. Tomlins4, Daniel R. Rhodes4, Nolan Priedigkeit5,6, Adrian V. Lee5,6, Steffi Oesterreich5,6, Linda M. McAllister-Lucas1,*, and Peter C. Lucas1,* 1Departments of Pathology and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 2Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania 3McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 4Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 5Women’s Cancer Research Center, Magee-Womens Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 6Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Current address for P.C. Delekta: Department of Microbiology & Molecular Genetics, Michigan State University, East Lansing, Michigan Current address for D.R. Rhodes: Strata
    [Show full text]
  • Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.22.109017; this version posted May 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Assessment of NR4A Ligands that Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1 Paola Munoz-Tello 1, Hua Lin 2,3, Pasha Khan 2, Ian Mitchelle S. de Vera 1,4, Theodore M. Kamenecka 2, and Douglas J. Kojetin 1,2,* 1 Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, FL, 33458, USA 2 Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, USA 3 Current address: Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou 350117, China 4 Current address: Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA * Correspondence: [email protected] as ligands that increase Nurr1 transcription in human neuroblastoma SK- ABSTRACT N-BE(2)-C cells (11). Amodiaquine improves behavioral alterations in a Nurr1/NR4A2 is an orphan nuclear receptor transcription factor im- Parkinson’s disease animal model (11) and improves neuropathology and plicated as a potential drug target for neurological disorders including memory impairment in an Alzheimer’s disease animal model (12). Alzheimer’s and Parkinson’s diseases. Previous studies identified small molecule modulators of NR4A nuclear receptors including Nurr1 and Amodiaquine is the most potent and efficacious Nurr1 agonist of the Nur77/NR4A1; it remains unclear whether these ligands affect Nurr1 4-amino-7-chloroquinoline compounds, but these compounds are not through direct binding or indirect non-binding mechanisms.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Utilization of Genomic Sequencing for Population Screening of Immunodeficiencies in the Newborn
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Utilization of genomic sequencing for population screening of immunodeficiencies in the newborn Ashleigh R. Pavey, MD1,2,3, Dale L. Bodian, PhD3, Thierry Vilboux, PhD3, Alina Khromykh, MD3, Natalie S. Hauser, MD3,4, Kathi Huddleston, PhD3, Elisabeth Klein, DNP3, Aaron Black, MS3, Megan S. Kane, PhD3, Ramaswamy K. Iyer, PhD3, John E. Niederhuber, MD3,5 and Benjamin D. Solomon, MD3,4,6 Purpose: Immunodeficiency screening has been added to many Results: WGS provides adequate coverage for most known state-directed newborn screening programs. The current metho- immunodeficiency-related genes. 13,476 distinct variants and dology is limited to screening for severe T-cell lymphopenia 8,502 distinct predicted protein-impacting variants were identified disorders. We evaluated the potential of genomic sequencing to in this cohort; five individuals carried potentially pathogenic augment current newborn screening for immunodeficiency, – variants requiring expert clinical correlation. One clinically including identification of non T cell disorders. asymptomatic individual was found genomically to have comple- Methods: We analyzed whole-genome sequencing (WGS) and ment component 9 deficiency. Of the symptomatic children, one clinical data from a cohort of 1,349 newborn–parent trios by was molecularly identified as having an immunodeficiency condi- genotype-first and phenotype-first approaches. For the genotype- tion and two were found to have other molecular diagnoses. first approach, we analyzed predicted protein-impacting variants in Conclusion: Neonatal genomic sequencing can potentially aug- 329 immunodeficiency-related genes in the WGS data. As a ment newborn screening for immunodeficiency. phenotype-first approach, electronic health records were used to identify children with clinical features suggestive of immunodefi- Genet Med advance online publication 15 June 2017 ciency.
    [Show full text]
  • Chromosomal Instability in Acute Myeloid Leukemia
    cancers Review Chromosomal Instability in Acute Myeloid Leukemia Mateus de Oliveira Lisboa 1 , Paulo Roberto Slud Brofman 1, Ana Teresa Schmid-Braz 2, Aline Rangel-Pozzo 3,* and Sabine Mai 3,* 1 Core for Cell Technology, School of Medicine, Pontifícia Universidade Católica do Paraná—PUCPR, Curitiba 80215-901, Paraná, Brazil; [email protected] (M.d.O.L.); [email protected] (P.R.S.B.) 2 Hospital das Clínicas, Universidade Federal do Paraná, Curitiba 80060-240, Paraná, Brazil; [email protected] 3 Department of Physiology and Pathophysiology, University of Manitoba, Cell Biology, CancerCare Manitoba Research Institute, Winnipeg, MB R3C 2B7, Canada * Correspondence: [email protected] (A.R.-P.); [email protected] (S.M.); Tel.: +1-(204)787-4125 (S.M.) Simple Summary: Chromosome instability (CIN) is an increased rate where chromosome acquire alterations due to errors in cell division. CIN creates genetic and cytogenetic diversity and is a common feature in hematological malignancies such as acute myeloid leukemia (AML). Low to moderate levels of CIN seems to be well tolerated and can promote cancer proliferation, genetic diversity, and tumor evolution. However, high levels of CIN seems to be lethal, where enhancing CIN could improve AML treatment. However, little is known about CIN in AML. Our review focus on CIN studies in AML, their prognostic results, as well as the use of CIN as a therapeutic target in AML. Abstract: Chromosomal instability (CIN), the increasing rate in which cells acquire new chromoso- mal alterations, is one of the hallmarks of cancer. Many studies highlighted CIN as an important Citation: de Oliveira Lisboa, M.; mechanism in the origin, progression, and relapse of acute myeloid leukemia (AML).
    [Show full text]
  • Adipose Tissue NAPE-PLD Controls Fat Mass Development by Altering the Browning Process and Gut Microbiota
    ARTICLE Received 11 Jul 2014 | Accepted 4 Feb 2015 | Published 11 Mar 2015 DOI: 10.1038/ncomms7495 OPEN Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota Lucie Geurts1, Amandine Everard1,*, Matthias Van Hul1,*, Ahmed Essaghir2, Thibaut Duparc1, Se´bastien Matamoros1, Hubert Plovier1, Julien Castel3, Raphael G.P. Denis3, Marie Bergiers1, Ce´line Druart1, Mireille Alhouayek4, Nathalie M. Delzenne1, Giulio G. Muccioli4, Jean-Baptiste Demoulin2, Serge Luquet3 & Patrice D. Cani1 Obesity is a pandemic disease associated with many metabolic alterations and involves several organs and systems. The endocannabinoid system (ECS) appears to be a key regulator of energy homeostasis and metabolism. Here we show that specific deletion of the ECS synthesizing enzyme, NAPE-PLD, in adipocytes induces obesity, glucose intolerance, adipose tissue inflammation and altered lipid metabolism. We report that Napepld-deleted mice present an altered browning programme and are less responsive to cold-induced browning, highlighting the essential role of NAPE-PLD in regulating energy homeostasis and metabolism in the physiological state. Our results indicate that these alterations are mediated by a shift in gut microbiota composition that can partially transfer the phenotype to germ-free mice. Together, our findings uncover a role of adipose tissue NAPE-PLD on whole-body metabolism and provide support for targeting NAPE-PLD-derived bioactive lipids to treat obesity and related metabolic disorders. 1 Metabolism and Nutrition Research Group, WELBIO-Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Universite´ catholique de Louvain, Avenue E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium. 2 de Duve Institute, Universite´ catholique de Louvain, Avenue Hippocrate, 74 B1.74.05, 1200 Brussels, Belgium.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Acot13 (NM 025790) Mouse Untagged Clone – MC203714 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for MC203714 Acot13 (NM_025790) Mouse Untagged Clone Product data: Product Type: Expression Plasmids Product Name: Acot13 (NM_025790) Mouse Untagged Clone Tag: Tag Free Symbol: Acot13 Synonyms: 0610006O17Rik; Them2 Vector: PCMV6-Kan/Neo E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin Fully Sequenced ORF: >BC018165 TGATCATCTAGGACCAGGGCGACCGGGGCGCGCGATCCTTTCTCCCGAGCACGACGCGACACCGCCCGGG CTTGCAGACTTGACCTTCCACACCCTTGTCCTCTCACAAACGTCTCTTCCAGAGTTCACTCTCGCAGAGC CCAGACTCTTGCTTTGCGTCCACGATGAGCAGCATGACCCAGAACCTACGAGAAGTAATGAAGGTTATGT TCAAAGTTCCCGGTTTTGATAGAGTTTTGGAAAAGGTGACGCTTGTCTCGGCTGCTCCTGAGAAACTAAT CTGTGAGATGAAGGTGGAGGAGCAGCATACTAATAAGCTGGGTACGCTCCATGGAGGCTTGACAGCAACC TTAGTGGACAGCATCTCGACCATGGCTCTAATGTGCACAGAAAGAGGAGCACCCGGAGTCAGTGTGGACA TGAACATAACGTACATGTCACCTGCTAAGATAGGAGAAGAAATAGTGATCACAGCACACATTCTGAAGCA AGGAAAGACACTTGCATTTGCCTCAGTGGATCTGACCAACAAGACCACAGGAAAATTAATAGCACAAGGC AGACACACAAAACACCTGGGGAACTGAGAACAGCGGGAAGACCCGAAGAAGCCCAACAATGCCAAGTATG GTTTGTGAACAACTTTCTGAAATAAATTATCAAAACCAGAAAAAAAAAAAAAAAAAAAA Restriction Sites: RsrII-NotI ACCN: NM_025790 Insert Size: 423 bp OTI Disclaimer: Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g.,
    [Show full text]